Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Omidubicel vs standard umbilical cord transplantation

Usama Gergis • 24 Apr 2022
The 2022 Tandem Meetings
General Omidubicel

Omidubicel is an in vitro platform used to expand umbilical cord stem cells. In this video, Usama Gergis, MD, MBA, Thomas Jefferson University, Philadelphia, PA, discusses the results of a Phase III study comparing omidubicel to standard umbilical cord blood transplantation. The study showed that omidubicel significantly increased stem cell expansion and reduced the time to neutrophil and platelet engraftment. Importantly, Dr Gergis explains that 40% of patients in this study were from ethnic minorities. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Usama Gergis

3:38
The impact of omidubicel on access to allogeneic transplantation
Usama Gergis • 24 Apr 2022
1:08
Racial and ethnic disparities in alloHSCT
Usama Gergis • 24 Apr 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals